Description

Simple

Clinical

Overview

Gaboxadol also known as 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) is an experimental sleep aid drug developed by Lundbeck and Merck, who reported increased deep sleep without the reinforcing effects of benzodiazepines. Development of Gaboxadol was stopped in March 2007 after concerns regarding safety and efficacy. It acts on the GABA system, but in a seemingly different way from benzodiazepines and other sedatives.

Pharmacology

Indication

Investigated for use/treatment in sleep disorders and insomnia.

Pharmacodynamic

Information currently not available.

Mechanism of action

Information currently not available.

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Gaboxadol
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
2,5-Dimethoxy-4-ethylthioamphetamine
The risk or severity of adverse effects can be increased when Gaboxadol is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
3-isobutyl-1-methyl-7H-xanthine
Gaboxadol may increase the excretion rate of 3-isobutyl-1-methyl-7H-xanthine which could result in a lower serum level and potentially a reduction in efficacy.
4-Bromo-2,5-dimethoxyamphetamine
The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Gaboxadol.
4-Methoxyamphetamine
The risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Gaboxadol.
5-methoxy-N,N-dimethyltryptamine
The risk or severity of adverse effects can be increased when Gaboxadol is combined with 5-methoxy-N,N-dimethyltryptamine.
6-O-benzylguanine
Gaboxadol may increase the excretion rate of 6-O-benzylguanine which could result in a lower serum level and potentially a reduction in efficacy.
7-Deazaguanine
Gaboxadol may increase the excretion rate of 7-Deazaguanine which could result in a lower serum level and potentially a reduction in efficacy.
7-Nitroindazole
The risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Gaboxadol.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
The risk or severity of adverse effects can be increased when Gaboxadol is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
7,9-Dimethylguanine
Gaboxadol may increase the excretion rate of 7,9-Dimethylguanine which could result in a lower serum level and potentially a reduction in efficacy.
8-azaguanine
Gaboxadol may increase the excretion rate of 8-azaguanine which could result in a lower serum level and potentially a reduction in efficacy.
8-chlorotheophylline
Gaboxadol may increase the excretion rate of 8-chlorotheophylline which could result in a lower serum level and potentially a reduction in efficacy.
9-Deazaguanine
Gaboxadol may increase the excretion rate of 9-Deazaguanine which could result in a lower serum level and potentially a reduction in efficacy.
9-Methylguanine
Gaboxadol may increase the excretion rate of 9-Methylguanine which could result in a lower serum level and potentially a reduction in efficacy.
Acefylline
Gaboxadol may increase the excretion rate of Acefylline which could result in a lower serum level and potentially a reduction in efficacy.
Acepromazine
The risk or severity of adverse effects can be increased when Acepromazine is combined with Gaboxadol.
Aceprometazine
The risk or severity of adverse effects can be increased when Aceprometazine is combined with Gaboxadol.
Acetazolamide
The risk or severity of adverse effects can be increased when Acetazolamide is combined with Gaboxadol.
Acetophenazine
The risk or severity of adverse effects can be increased when Acetophenazine is combined with Gaboxadol.
Acetylglycinamide chloral hydrate
The risk or severity of adverse effects can be increased when Gaboxadol is combined with Acetylglycinamide chloral hydrate.